FOXO1 and hepatocellular carcinoma: And FOXO1 has ability to stabilize the liver microenvironment and reduce HCC recurrence by inhibiting the polarization and function of Th17 cells, which may be used as a potential therapeutic target to alleviate IRI-induced HCC recurrence.